Ameen Angie M, Elkazaz Amany Y, Mohammad Hala M F, Barakat Bassant M
a Department of Physiology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
b Medical Biochemistry Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Can J Physiol Pharmacol. 2017 Jul;95(7):819-829. doi: 10.1139/cjpp-2016-0158. Epub 2017 Mar 1.
There is evidence that inflammation and oxidative stress contribute to the neurodegenerative changes observed in Parkinson's disease. Unfortunately, there is a lack of curative treatment for this debilitating movement disorder. Boswellic acids (BAs) are pentacyclic triterpene molecules of plant origin that have been utilized for treating many inflammatory conditions. The current study was conducted to explore the protective role of BAs against rotenone-induced experimental parkinsonism. Twenty-four rats were assigned to one of four treatment groups. The first two groups were a vehicle group (no rotenone) and a rotenone control group in which rats received rotenone (1 mg/kg) every 48 h. The next 2 groups received rotenone (1 mg/kg every 48 h) plus protective oral doses of BAs (125 or 250 mg/kg daily). Rats in the rotenone group showed motor dysfunction when tested in the open-field arena and cylinder and rotarod tests. Moreover, inflammatory markers increased, whereas the dopamine level was lower in the striata of rats in the rotenone group versus those in the vehicle group. BAs taken by rats with rotenone-induced parkinsonism showed enhanced general motor performance, reduced inflammatory markers, and increased striatal dopamine level and nigral tyrosine hydroxylase immunostaining. In conclusion, BAs are promising agents in slowing the progression of Parkinson's disease if appropriate data become available about their safety and efficacy in humans.
有证据表明，炎症和氧化应激会导致帕金森病中观察到的神经退行性变化。不幸的是，对于这种使人衰弱的运动障碍缺乏治愈性治疗方法。乳香酸（BAs）是植物来源的五环三萜分子，已被用于治疗多种炎症性疾病。本研究旨在探讨BAs对鱼藤酮诱导的实验性帕金森病的保护作用。将24只大鼠分为四个治疗组之一。前两组分别为溶剂对照组（无鱼藤酮）和鱼藤酮对照组，其中大鼠每48小时接受一次鱼藤酮（1 mg/kg）。接下来的两组接受鱼藤酮（每48小时1 mg/kg）加保护性口服剂量的BAs（每日125或250 mg/kg）。在旷场试验、圆筒试验和转棒试验中，鱼藤酮组的大鼠表现出运动功能障碍。此外，鱼藤酮组大鼠纹状体中的炎症标志物增加，而多巴胺水平低于溶剂对照组。鱼藤酮诱导的帕金森病大鼠服用BAs后，其总体运动表现增强，炎症标志物减少，纹状体多巴胺水平升高，黑质酪氨酸羟化酶免疫染色增加。总之，如果能获得关于BAs在人体中的安全性和有效性的适当数据，那么它们有望成为减缓帕金森病进展的药物。
